Table 1.
Patient characteristics.
| Number | |
|---|---|
| Patients | 40 |
| Male | 3 |
| Female | 37 |
| Site of disease and stage | |
| Breast cancer stage II or III | 14 |
| Breast cancer stage IV | 19 |
| Ovarian cancer | 4 |
| Germ cell cancer | 3 |
| Courses with pharmacokinetic data available | 65 |
| 1st course CTC | 20 |
| 2nd course CTC | 1 |
| 1st course tCTC | 20 |
| 2nd course tCTC | 15 |
| 3rd course tCTC | 91 |
| Total thioTEPA dose, number of courses | |
| 480 mg m−2 (CTC) | 21 |
| 320 mg m−2 (tCTC) | 43 |
| 240 mg m−2 (3rd course tCTC with dose reduction) | 1 |
| Median age (years) (range) | 46 (16–58) |
| Median body surface area (m2) (range) | 1.79 (1.55–1.98) |
| Median weight (kg) (range) | 68 (52–90) |
| Medium height (cm) (range) | 170 (155–185) |
| Median serum creatinine (µm) (range) | 66 (53–89) |
| Median creatinine clearance Cockcroft-Gault (ml min−1) (range) | 102 (64–162) |
| Median alanine amino transferase (U l−1) (range) | 20 (4–100) |
| Median aspartate amino transferase (U l−1) (range) | 12 (7–59) |
| Median alkaline phosphatase (U l−1) (range) | 57 (25–103) |
| Median lactate dehydrogenase (U l−1) (range) | 209 (154–504) |
| Median serum bilirubine (µm) (range) | 7 (5–21) |
| Median serum total protein (g l−1) (range) | 61 (54–77) |
| Median serum albumin (g l−1) (range) | 42 (38–48) |
| Median gamma glutamyl transferase (U l−1) (range) | 27 (7–254) |
| Number of thioTEPA concentrations | 1115 |
| Number of TEPA concentrations | 915 |
1
One third course of tCTC given without cyclophosphamide.